Journal Mobile Options
Table of Contents
Vol. 24, No. 4, 2002
Issue release date: July–August (December 2002)
Section title: Original Paper
Dev Neurosci 2002;24:262–271
(DOI:10.1159/000066740)

Enhanced Epileptogenic Susceptibility in a Genetic Model of Reactive Synaptogenesis: The Spastic Han-Wistar Rat

Cepeda C. · Crawford C.A. · Margulies J.E. · Watson J.B. · Levine M.S. · Cohen R.W.
aMental Retardation Research Center, University of California, Los Angeles; bDepartment of Psychology, California State University, San Bernardino; cDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, and dDepartment of Biology, California State University, Northridge, Calif., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 9.00
Account: USD 8.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/29/2002
Accepted: 5/15/2002
Published online: 12/6/2002

Number of Print Pages: 10
Number of Figures: 5
Number of Tables: 1

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: http://www.karger.com/DNE

Abstract

Our laboratory has been studying the spastic Han-Wistar (sHW) rat as a model of neuronal degeneration. Mutant sHW rats display a number of developmental abnormalities that eventually lead to hippocampal pyramidal cell death and synaptic reorganization starting around 30 days of age. The present study examined the contribution of hippocampal reorganization to the expression of seizures induced by systemic injections of kainic acid. Behavioral observations, EEG recordings and hippocampal Fos protein expression in these animals indicated that mutants develop paroxysmal discharges and seizures earlier than controls and the intensity of epileptic manifestations is greater. Kainate injections were lethal in 50% of mutants compared to only 5% of controls. Fos expression was increased approximately twofold in the mutant hippocampus, implicating abnormal excitation in this region. Additional studies in untreated animals indicated that GluR2 mRNA expression was significantly increased throughout the hippocampus in mutant animals, possibly contributing to the enhanced susceptibility to kainate treatment. These results confirm the role of synaptic reorganization in the increased propensity to develop epileptic discharges. Our data also underscore the usefulness of this natural model of cell degeneration and reactive synaptogenesis for understanding the mechanisms of neuronal hyperexcitability.


  

Author Contacts

Carlos Cepeda, PhD
Mental Retardation Research Center
760 Westwood Plaza, NPI 58-258, University of California Los Angeles
Los Angeles, CA 90095 (USA)
Tel. +1 310 206 0861, Fax +1 310 206 5060, E-Mail ccepeda@mednet.ucla.edu

  

Article Information

Received: Received: April 29, 2002
Accepted: May 15, 2002
Number of Figures : 5, Number of Tables : 1, Number of References : 34

  

Publication Details

Developmental Neuroscience

Vol. 24, No. 4, Year 2002 (Cover Date: July-August (Released December 2002))

Journal Editor: A.T. Campagnoni, Los Angeles, Calif.
ISSN: 0378–5866 (print), 1421–9859 (Online)

For additional information: http://www.karger.com/journals/dne


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/29/2002
Accepted: 5/15/2002
Published online: 12/6/2002

Number of Print Pages: 10
Number of Figures: 5
Number of Tables: 1

ISSN: 0378-5866 (Print)
eISSN: 1421-9859 (Online)

For additional information: http://www.karger.com/DNE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.